1. Home
  2. CRDF vs THRY Comparison

CRDF vs THRY Comparison

Compare CRDF & THRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

SELL

Current Price

$0.87

Market Cap

67.1M

Sector

Health Care

ML Signal

SELL

Logo Thryv Holdings Inc.

THRY

Thryv Holdings Inc.

HOLD

Current Price

$0.74

Market Cap

55.5M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRDF
THRY
Founded
1999
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Industrial Machinery/Components
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
67.1M
55.5M
IPO Year
2012
2020

Fundamental Metrics

Financial Performance
Metric
CRDF
THRY
Price
$0.87
$0.74
Analyst Decision
Buy
Hold
Analyst Count
5
4
Target Price
★ $5.14
$3.17
AVG Volume (30 Days)
★ 1.0M
497.3K
Earning Date
11-12-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
27.37
★ 100.50
EPS
★ N/A
N/A
Revenue
$365,993.00
★ $785,015,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 49.61
N/A
52 Week Low
$0.71
$0.67
52 Week High
$3.31
$6.28

Technical Indicators

Market Signals
Indicator
CRDF
THRY
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
CRDF
THRY

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

About THRY Thryv Holdings Inc.

Thryv Holdings Inc is dedicated to supporting local, independent service-based businesses and emerging franchises by providing a cloud-based software platform, and marketing solutions to entrepreneurs. The group are provider of SaaS all-in-one small business management software in addition to providing print and digital marketing solutions to SMBs. Its solutions enable small and medium-sized business clients to attract and generate new business leads, manage their customer relationships efficiently with artificial intelligence (AI) tools and automation. The group has two business segments; Thryv SaaS deriving maximum revenue and Thryv Marketing Services.

Share on Social Networks: